UNSPSC 51281817: Doxorubicin aglycone

This classification denotes a doxorubicin preparation with the molecular formula C21H18O9, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier X023T6C35L, chemically known as 5,12-naphthacenedione, 7,8,9,10-tetrahydro-6,8,10,11-tetrahydroxy-8-(2-hydroxyacetyl)-1-methoxy-, (8s,10s)-, but more generally known as doxorubicin aglycone, which bears US NIH Compound Identifier 72401. European Medicines Agency schedules doxorubicin aglycone or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06391MIG.

Most nations, for tariff purposes, schedule doxorubicin aglycone under HS 29419000. SMILES: COC1CCCC2C1C(=O)C3C(C(C4C(C3O)[C@H](C[C@@](C4)(C(=O)CO)O)O)O)C2=O.

UNSPSC 51281817 Doxorubicin aglycone is a Commodity code that covers the procurement of specific pharmaceutical active pharmaceutical ingredients and related drug compounds by state and local health agencies. The recent activity under this code shows that state and local governments are acquiring pharmaceutical products through cooperative purchasing agreements and competitive bidding processes, often leveraging multi-state or regional purchasing consortiums to access inventory at negotiated rates. The Illinois Department of Public Health and Seminole County, Florida represent the issuing bodies active in this space — a state health department and a county government — both using established procurement vehicles (piggyback contracts and invitation for bid) to secure pharmaceutical supplies for emergency preparedness and community health programs.

The recent opportunities cluster in Illinois and Florida. The Illinois Department of Public Health awarded a piggyback pharmaceutical warehouse contract to Chartwell Rx LLC on August 28, 2026, through the MMCAP Infuse consortium for a total of $2,999,999.11 over three years; although the award is complete, the notice indicates that state health departments source pharmaceutical products through multi-year piggyback arrangements with renewal options. Seminole County, Florida issued an IFB on June 30, 2026, for 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually with quarterly deliveries, indicating that county health systems procure pharmaceutical and related health-safety products on fixed-fee contracts with two-year initial terms and one-year renewal options. Vendors must meet E-Verify compliance, drug-free workplace certification, and appropriate insurance requirements; FEMA funding may apply to some county procurements, introducing additional federal compliance obligations.